Back
Compare AU
Compare VSO vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard MSCI Australian Small Companies Index ETF (VSO) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VSO | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 309 | 73 |
Median incremental investment | $999.53 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,865.96 | $2,343.60 |
Average age group | > 35 | > 35 |
Key Summary
VSO | CURE | |
|---|---|---|
Strategy | VSO.AX was created on 2011-05-23 by Vanguard. The fund's investment portfolio concentrates primarily on small cap equity. Vanguard MSCI Australian Small Companies Index ETF seeks to track the return of the MSCI Australian Shares Small Cap Index before taking into account fees, expenses and tax. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | carsales.com Ltd. (2.47 %) Atlas Arteria Ltd. (2.42 %) Allkem Ltd. (2.38 %) | Twist Bioscience Corp (1.73 %) Oruka Therapeutics Inc (1.57 %) Apogee Therapeutics Inc (1.53 %) |
Top 3 industries | Materials (24.32 %) Industrials (14.76 %) Financials (12.31 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (98.27 %) United Kingdom of Great Britain and Northern Ireland (0.95 %) United States (0.69 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.3 % | 0.45 % |
Key Summary
VSO | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | MSCI Australian Shares Small Cap Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.3 % | 0.45 % |
Price | $75.42 | $75.60 |
Size | N/A | $49.167 million |
10Y return | 49.52 % | N/A |
Annual distribution yield (5Y) | 4.87 % | 0.03 % |
Market | ASX | ASX |
First listed date | 26/05/2011 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VSO | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 309 | 73 |
Median incremental investment | $999.53 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,865.96 | $2,343.60 |
Average age group | > 35 | > 35 |
Pros and Cons
VSO | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VSO | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |